Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute promyelocytic leukemia

American Journal of Clinical Pathology

Volumn 123, Issue 6, 2005, Pages 840-848

  Yin, C Cameron ^a   Glassman, Armand B ^a   Lin, Pei ^a   Valbuena, Jose R ^a   Jones, Dan ^a   Luthra, Rajyalakshmi ^a   Medeiros, L Jeffrey ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute promyelocytic leukemia; APL; Cytogenetic abnormalities; Dysplasia; flt3; PML RAR ; Therapy related

Indexed keywords

ADULT; ARTICLE; BONE MARROW BIOPSY; CELL MATURATION; CHEMOTHERAPY; CLINICAL ARTICLE; CYTOGENETICS; DYSERYTHROPOIESIS; DYSPLASIA; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GRANULOCYTE; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOPHENOTYPING; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 19644372757     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/TJFFK819RPCLFKJ0     Document Type: Article

References (24)

1. Brunning RD, Matures E, Harris NL, et al. Acute promyelocytic leukaemia (AML with t(15;17)(q22;q21);(PML/RARα) and variants). In: Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:84-86.
2. Gallagher RE, Yeap BY, Bi W, et al. Quantitative real-time RT-PCR analysis of pml/rarα mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from Intergroup Protocol 0129. Blood. 2003;101:2521-2528.
3. Schnittger S, Weisser M, Schoch C, et al. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFB-MYH11+ acute myeloid leukemia based on quantification effusion transcripts. Blood. 2003:102:2746-2755.
4. Pantic M, Novak A, Marisavljevic D, et al. Additional chromosome aberrations in acute promyelocytic leukemia: characteristics and prognostic influence. Med Oncol. 2000;17:307-313.
5. Gallagher RE, Willman CL, Slack JL, et al. Association of pml/rarα fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood. 1997;90:1656-1663.
6. Schoch C, Haase D, Haferlach T, et al. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol. 1996;94:493-500.
7. Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol. 2003;21:2123-2137.
8. Detourmignies L, Castaigne S, Stoppa AM, et al. Therapy-related acute promyelocytic leukemia: a report on 16 cases. J Clin Oncol. 1992;10:1430-1435.
9. Pollicardo N, O'Brien S, Estey EH, et al. Secondary acute promyelocytic leukemia: characteristics and prognosis of 14 patients from a single institution. Leukemia. 1996;10:27-31.
10. Yin CC, Medeiros LJ, Classman AB, et al. t(8;21)(q22;q22) in blast phase of chronic myelogenous leukemia. Am J Clin Pathol. 2004;121:836-842.
11. Hao S, Sanger W, Onciu M, et al. Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features. Mod Pathol. 2002;15:1266-1272.
12. Mittleman F, ed. ISCN 1995: An International System for Human Cytogenetic Nomenclature 1995. Basel, Switzerland: S Karger; 1995.
13. Lin P, Hao S, Medeiros LJ, et al. Expression of CD2 in acute promyelocytic leukemia correlates with short form of pml/rarα transcripts and poorer prognosis. Am J Clin Pathol. 2004;121:402-407.
14. Gallagher RE, Li YP, Rao S, et al. Characterization of acute promyelocytic leukemia cases with pml/rarα break/fusion sites in pml exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood. 1995;86:1540-1547.
15. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97:89-94.
16. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of flt3 in human hematologic malignancies. Blood. 2001;97:2434-2439.
17. Haferlach T, Schoch C, Loffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: result of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol. 2003;21:256-265.
18. Pedersen-Bjergaard J, Andersen MK, Johansson B. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J Clin Oncol. 1998;16:1897-1898.
19. Schoch C, Kern W, Schnittger S, et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2004;18:120-125.
20. Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago Series. Blood. 2003;102:43-52.
21. Pedersen-Bjergaard J, Philip P, Larsen SO, et al. Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood. 1990;76:1083-1091.
22. Rennert H, Golde T, Wilson RB, et al. A novel, non-nested reverse-transcriptase polymerase chain reaction (RT-PCR) test for the detection of the t(15;17) translocation: a comparative study of RT-PCR cytogenetics, and fluorescence in situ hybridization. Mol Diagn. 1999;4:195-209.
23. Au WY, Fung AT, Ma ES, et al. Low frequency of flt3 gene internal tandem duplication and activating loop mutation in therapy-related acute myelocytic leukemia and myelodysplastic syndrome. Cancer Genet Cytogenet. 2004;149:169-172.
24. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol. 2002;39:6-11.